Growth in recent years has largely been supported by price increases and new product introductions even as volume growth has been negative or 2-3 per cent at best. Acute therapies, accounting for 62-65 per cent of the IPM, have continued to outpace growth in chronic therapies since FY2022. However, the trend is expected to reverse going forward.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/U2IhkHz
No comments:
Post a Comment